삼성바이오로직스207940.KS

삼성바이오로직스 2026년 2분기 실적: 매출 30% 급증해 1조 3,209억 원, 상반기 영업이익 1조 1,700억 원 돌파

삼성바이오로직스가 2026년 2분기 매출 1조 3,209억 원(전년 대비 +30.2%), 영업이익 5,864억 원(+22.9%)을 기록하며 시장 컨센서스에 부합하는 실적을 발표했다. 상반기 누적 매출은 2조 5,780억 원으로, 연간 15~20% 성장 가이던스의 상단에 근접하고 있다.

Samsung Biologics Bets $2.0 Billion on Swiss Peptide Maker PolyPeptide to Enter the GLP-1 Supply Chain

Samsung Biologics (207940.KS), the Songdo-based contract drug manufacturer within Korea's Samsung group, has agreed to acquire 100% of PolyPeptide Group AG, a Swiss-headquartered contract developer and manufacturer of therapeutic peptides, in the largest M&A ever struck by a Korean pharmaceutical or...

Korea Claims No. 2 FDA Biosimilar Slot as Samsung Biologics' $280M U.S. Plant Anchors Next Growth Phase

Korea holds 19 FDA biosimilar approvals (No. 2 globally). Samsung Biologics completes $280M GSK Rockville acquisition, raising total CDMO capacity to 845,000L. H1 2026 saw 6 new approvals vs 18 in 2025.

Samsung Biologics (207940.KS) Union Quits Group Coalition

Samsung Biologics Unveils Four Drug Delivery Platforms at BIO USA 2026, Targeting Technology Licensing as New Revenue Pillar

Samsung Biologics presented four proprietary drug delivery platforms at BIO USA 2026, signaling a push into technology licensing to diversify revenue beyond contract manufacturing.

Samsung Biologics CEO Reaffirms 15-20% Growth Target at BIO USA 2026, Advances Rockville Ramp and Netherlands Hub

Samsung Biologics CEO John Rim unveiled a three-pillar global expansion at BIO USA 2026: Rockville integration (USD 280M, 60,000L), Netherlands hub (Q3 2026), and Songdo Plant 6 decision by year-end, targeting 1.3 million liters by 2032.

Samsung Biologics Secures KRW 149.1 Billion in CMO Add-Ons as Union Plans Independence Vote

Samsung Biologics disclosed two DART-filed CMO contract expansions totaling KRW 149.1 billion in June 2026, lifting its cumulative backlog to ~USD 10.4 billion, even as the labor union prepares a vote to exit Samsung Group's conglomerate union.

Samsung Biologics Returns to BIO USA for 14th Straight Year, Backed by Record Revenue and a $21 Billion Order Book

Samsung Biologics (207940.KS), the Songdo-based contract drug manufacturer that ranks as the world's largest biopharmaceutical producer by installed c

K-Biotech's Animal-Free Pivot: Samsung Biologics and Peers Race to Meet New FDA and EU Drug Rules

The EU and FDA are converging on a phaseout of animal testing in drug development, creating a new competitive arena where Samsung Biologics and a cohort of Korean biotech firms are building organoid and AI capabilities to stay ahead.

Samsung Biologics (207940.KS) Backs ₩200B Third Bio Fund

Samsung Electronics' ₩600M Bonus Resets the Math for Samsung Biologics Strike Talks

The tentative wage deal that pulled Samsung Electronics — Korea's largest chipmaker — back from an 18-day general strike has handed the still-striking union at Samsung Biologics — Korea's largest cont

Samsung Biologics Wage Impasse Lingers After Electronics' 12% Profit-Share Reset

Samsung Biologics (KRX: 207940), Korea's largest contract drug manufacturer (CDMO), has not yet matched the wage settlement its memory-chip affiliate concluded

Samsung Biologics Pegs Strike Damage at ₩150 Billion ($102 Million) as Labor Unrest Spreads to Kakao

Samsung Biologics Files Criminal Complaint Against Striking Union Chair Over Leaked PR Records

Samsung Biologics (207940.KS) filed a criminal complaint against union chair Park Jae-sung for leaking PR-department tax invoice records and defamation, per Yonha...

Samsung Biologics (207940.KS) Files Criminal Complaint on Strike

Samsung Biologics filed a criminal complaint against six union members, including the branch chair, alleging obstruction during last week's first-ever strike.

Samsung Biologics' First-Ever Strike Halts Cancer-Drug Output, Company Cites ₩150 Billion Loss

Samsung Biologics Partial Strike Extends Into Day Three; Full Walkout Set for May 1